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Abstract
Background: Inflammatory bowel diseases (IBDs) are group of chronic inflammatory illnesses with a remitting and
relapsing course that may result in appreciable morbidity and high medical costs secondary to repeated
hospitalizations. The study’s objectives were to identify the reasons for hospitalization among patients with
inflammatory bowel diseases, and compare inpatient courses and readmission rates for IBD-related admissions
versus non-IBD-related admissions.
Methods: A retrospective chart review was performed on all patients with IBD admitted to the Minneapolis VA
Medical Center between September 2010 and September 2012.
Results: A total of 111 patients with IBD were admitted during the 2-year study period. IBD flares/complications
accounted for 36.9 % of the index admissions. Atherothrombotic events comprised the second most common
cause of admissions (14.4 %) in IBD patients. Patients with an index admission directly related to IBD were
significantly younger and had developed IBD more recently. Unsurprisingly, the IBD admission group had
significantly more gastrointestinal endoscopies and abdominal surgeries, and was more likely to be started on
medication for IBD during the index stay. The median length of stay (LOS) for the index hospitalization for an IBD
flare or complication was 4 (2–8) days compared with 2 (1–4) days for the other patients (P = 0.001). A smaller
percentage of the group admitted for an IBD flare/complication had a shorter ICU stay compared with the other
patients (9.8 % vs. 15.7 %, respectively); however, their ICU LOSs tended to be longer (4.5 vs. 2.0 days, respectively,
P = 0.17). Compared to the other admission types, an insignificantly greater percentage of the group whose index
admission was related to an IBD flare or complication had at least one readmission within 6 months of discharge
(29 % versus 21 %; P = 0.35). The rate of admission was approximately 80 % greater in the group whose index
admission was related to an IBD flare or complication compared to the other types of admission (rate ratio 1.8,
95 % confidence interval 0.96 to 3.4), although this difference did not reach statistical significance (P = 0.07).
Conclusion: Identifying the reasons for the patients' index admission, IBD flares versus all other causes, may provide
valuable information concerning admission care and the subsequent admission history.
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Background
Inflammatory bowel diseases (IBDs) are a group of
chronic inflammatory illnesses with a remitting and re-
lapsing course that may result in appreciable morbidity
and high medical costs secondary to repeated hospitali-
zations. The clinical management of IBD patients has
improved due to increased understanding of the disease
process and new therapies. However, disease morbidity
remains high, with an estimated mean annual direct
health care cost per IBD patient in the US of roughly
$8265 and $5066 for Crohn’s disease (CD) and ulcerative
colitis (UC), respectively. Approximately 31 and 38 % of
these costs, respectively, are directly attributed to acute
hospitalization [1]. Within the Department of Veterans
Affairs (VA), there is an increasing burden of disease re-
lated to IBD. A recent study using VA administrative
data found that the prevalence of Crohn’s disease and ul-
cerative colitis had increased 2- to 3-fold among vet-
erans between 1998 and 2009 [2]. The VA population
differs from the general US population due to combat
exposure, male predominance, lower socio-economic
status, and higher psychiatric comorbidities [3], all of
which can potentially affect IBD progression and treat-
ment. There is a paucity of data on inpatient resource
utilization by veterans with IBD. We sought to identify
the reasons for hospitalization among patients with IBD
and to compare the inpatient course and readmission
rates for IBD-related admissions versus non-IBD-related
admissions. To this end, we conducted a clinical review
of all patients admitted to the tertiary care VA hospital
in Minneapolis, MN, USA, during the fiscal years 2010
and 2011 to assess the reasons for hospitalization, the
inpatient course and readmissions.
Methods
A retrospective chart review was conducted of all patients
with an IBD diagnosis admitted to the Minneapolis VA
Medical Center between September 2010 and September
2012. Ethics approval was granted for the chart review
by the Institutional Review Board at the Minneapolis
VAMC.
Patients were identified by the International Classifica-
tion of Diseases version 9 (ICD-9) diagnostic codes
representing Crohn’s disease (555.×) and ulcerative col-
itis (556.×). Hospitalization data were identified for 132
unique patients. Subjects with missing data on the index
hospitalization or patients determined not to have IBD
on chart review (n = 21) were excluded.
The patients’ demographics and disease histories were
obtained from the hospitalization and clinic notes in the
electronic medical records. The principle diagnosis for
each hospitalization was ascertained by a physician based
on the review of hospitalization records. The criteria for
defining an IBD flare/complication were as follows: any
hospitalization requiring steroids or other widely accepted
treatments for IBD, such as tumor necrosis factor (TNF)
inhibitors, and surgical procedures related to the intestinal
tract. In-hospital resource use was determined by LOS, in-
tensive care unit use (ICU) and recurrent hospitalizations
within 6 months.
Statistical analyses
Continuous variables were described by the mean and
standard deviation of the distribution unless they were
highly skewed, in which case the results were described
using medians and interquartile ranges (IQRs). Depend-
ing on the level of measurement and the data distribu-
tions, these groups were compared using a t-test, rank
sum test or Chi-square test. Six-month hospital readmis-
sion rates per 100 patient-months were estimated and
compared using Poisson regression.
Results
A total of 111 IBD patients were admitted during the 2-
year study period. IBD flares/complications accounted
for 41 (36.9 %) of the index admissions. Other reasons
for admission included atherothrombotic events (14.4 %),
non-GI infections (9.0 %), orthopedic surgery (6.3 %),
oncological reasons (5.4 %), arrhythmia (4.5 %), renal rea-
sons (acute kidney injury on chronic kidney disease 2/2
FTT, hemodialysis complications) (5.4 %), pulmonary rea-
sons (COPD, tracheobronchitis) (3.6 %), psychiatric rea-
sons (2.7 %), and miscellaneous causes (other surgeries,
non-stroke neurological reasons, elective procedure re-
quiring admission, giardiasis) (11.8 %). Table 1 compares
the characteristics of the patients whose index admissions
were for an IBD flare or complication versus patients
whose admissions were not directly related to IBD. Pa-
tients with an index admission directly related to IBD
were significantly younger and had developed IBD more
recently. Approximately half of each group had a psychi-
atric co-morbidity. Unsurprisingly, the IBD admission
group had significantly more gastrointestinal (GI) endos-
copies and abdominal surgeries and was more likely to be
started on medications for IBD during the index stay. The
median LOS (interquartile range) for the index hospitali-
zations for an IBD flare or complication was 4 (2–8) days,
whereas the LOS was 2 (1–4) days for the other patients
(P = 0.001). A smaller percentage of the group admitted
for an IBD flare or complication had an ICU stay [4/41
(9.8 %) vs. 11/70 (15.7 %)]; however, their ICU LOSs
tended to be longer [4.5d (2–6.5d) vs. 2d (1–2d), respect-
ively; P = 0.17]. There were no in-hospital deaths.
All-cause readmissions within 6 months after dis-
charge from the index admission are summarized in
Table 2. Compared to other types of admissions, an in-
significantly greater percentage of the group whose
index admission was related to an IBD flare or
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complication had at least one readmission within
6 months of discharge (29.2 % vs 21.4 %; P = 0.35). The
rate of admission was approximately 1.8 times greater in
the group whose index admission was related to an IBD
flare or complication compared to the other types of ad-
missions (rate ratio 1.8, 95%CI 0.96–3.40), although this
difference did not reach statistical significance (P = 0.07).
Discussion
Interventions designed to reduce the frequency of hospi-
talizations and the attendant medical costs of IBD pa-
tients require understanding the factors driving the
admission of these patients. To obtain these data, we an-
alyzed the reasons for hospitalization and the utilization
of inpatient healthcare resources by US veterans with
IBD. In this analysis, it became apparent that identifying
the reason for the patient’s index admission (IBD flare
versus all other causes) provided valuable information
concerning admission care and the subsequent admis-
sion history.
Several key findings deserve emphasis. First, out of the
111 IBD patients admitted to the hospital over a 2-year
period, only approximately 1/3 of the admissions were
for problems directly related to IBD; the other 2/3 of the
patients were admitted for a variety of non-IBD medical
problems, most commonly atherothrombotic conditions.
Because gastroenterologists tend to see patients with ac-
tive IBD, problems with IBD flares tend to monopolize
the attention of the physicians. These admission data
emphasize the frequency of non-IBD problems and the
need for care directed to the entire gamut of medical
conditions rather than a concentration simply on gastro-
intestinal problems. Of particular interest was the fre-
quency of atherothrombotic events in our patients with
quiescent IBD. Previous studies have found an increased
incidence of venous and arterial thrombotic events in
IBD patients [4], which may reflect the pro-thrombotic
state that has been postulated to be caused by low-grade
systemic inflammation [5].
Secondly, there was a strikingly increased prevalence
of opiate usage by patients admitted with a flare (17 %)
vs. only 4 % of patients admitted for non-IBD problems.
The 17 % prevalence seems high relative to Targownik
et al., [6] who reported a maximum of 11 % of IBD sub-
jects with an active opioid prescription in the first
Table 1 Baseline characteristics of patients by reason for index
hospital admission
Item IBD flare or
complication (n = 41)
Other type of
admission (n = 70)
Mean age (year) 54.5 ± 16.9** 64.7 ± 12.4
Male (n) 40 70




Type of IBD (n)
Ulcerative colitis 20 34
Crohn’s disease 21 36
IBD duration [n (%)]
New 2 (4.9)* 0 (0)
< 1 year 3 (7.3)* 1 (1.4)
> 1 year 35 (85.4)* 61 (87.1)
Unknown 1 (2.4)* 8 (11.4)
Psychiatric co-morbidity [n (%)] 23 (56.1) 31 (44.3)
Inpatient procedures [n (%)]
GI endoscopy 9 (22.0)* 5 (7.1)
Abdominal surgery 9 (22.0)* 4 (5.7)
Non-abdominal surgery 0** 15 (21.4)
Medications initiated in the hospital [n (%)]
Antibiotics 10 (24.4)** 3 (4.3)
Corticosteroids 14 (34.1)** 2 (2.9)
Thiopurines 2 (4.9)** 0
Biologics 2 (4.9)** 0
Discharge Medications
New medications added 37 (90.2)** 14 (20.0)
Changed dose 3 (7.3)** 1 (1.4)
New pain medications added 15 (36.6)** 6 (8.6)
Existing medications
discontinued
7 (17.1)** 4 (5.7)
*P < 0.05, **P < 0.001
Table 2 Readmissions within 6 months by reason for index
hospital admission






Number of readmissions in 6 months [n (%)]
0 29 (70.7) 55 (78.6)
1 7 (17.1) 12 (17.1)
2 3 (7.3) 2 (2.9)
3 1 (2.4) 1 (1.4)
4 1 (2.4) 0
Median time to first readmission in
months (IQR)
0.6 (0.3–3.1) 1.3 (0.3–4.0)
Number of patients readmitted [n (%)] 12 (29.3) 15 (21.4)
Total number of readmissions (n) 20 19
Total person-months a 242 414
Incidence rate of readmission (95 % CI)
per 100 person-months b
8.3 (5.2–3.1) 4.6 (2.8–0.3)
a Calculated by multiplying n to 5.92 (as data was collected in number of days)
b Rate ratio is calculated as the ratio between the two incidence rates of
readmission per 100 person-months
IQR interquartile range, CI confidence interval
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month following diagnosis, with this usage falling as the
disease process came under control. Several factors have
been shown to be associated with outpatient opioid use
in IBD populations, including psychiatric comorbidities,
such as depression and anxiety, a history of substance
abuse, female gender, and clinical disease activity when
measured by symptoms [7, 8]. Almost half of our cohort
had psychiatric comorbidities, which might account for
the higher prevalence of opioid use in this population.
Prior studies have also shown that opioid use may be as-
sociated with more severe disease [9, 10] and may be in-
dependently related to poor outcomes [9], although the
cause or effect relationship remains to be determined.
Finally, there are reports showing an overall increased
prevalence of opioid use in veteran populations, al-
though opiate use in veterans with IBD has not been
previously studied [11].
Third, we found that patients admitted for IBD flares
were more likely to have a longer LOS (both in the ICU
and overall). The average LOS reported by Kappelman
et al. [1] was 6.7 days for CD and 6.9 days for UC, al-
though this study did not identify the reasons for
hospitalization. The median LOS in our study was 4.0 days
for an IBD flare and 2.0 days for other admissions, which
was comparable to a recent Swiss study showing a mean
number of hospitalization days of 2.0 (±8.8) and 1.5 (±6.1)
for CD and UC, respectively. While it is tempting to
speculate that the shorter hospitalizations reflect recent
improvements in the medical management of IBD, con-
firmation of this speculation requires additional study. It
is well established that hospitalization for IBD exacerba-
tions can be resource-intensive, primarily due to the num-
ber of surgical procedures performed in this group [1].
We also found that patients admitted for IBD-related rea-
sons were significantly more likely to undergo endoscopic
and abdominal surgical procedures.
Fourth, patients with IBD-related admissions were more
likely to have significant changes in their medication pro-
files upon discharge from the hospital compared to pa-
tients with non-IBD-related admissions. This issue raises
concern over the possibility that a lack of appreciation of
such changes among patients or poor communication of
such changes to the outpatient providers could result in
disease mismanagement and potential readmissions or ur-
gent care visits. A randomized clinical trial demonstrated
that readmissions to hospitals were often related to defi-
ciencies in coordination and communication within the
health care system and with patients. Thus, we speculated
that good transitional care interventions to systematically
address communication and care-coordination and to
promote self-management in patients admitted for IBD
flares/complications could be of significant value.
The limitations of our study merit attention. We relied
on available clinical and administrative data to assess
and account for differences in illness severity at the patient
or hospital level. Thus, residual confounding cannot be
ruled out. Additionally, we were unable to ascertain the
necessity of hospitalization or the criteria used to decide
to readmit. It is possible that we underestimated the rate
of readmission if the veteran was re-hospitalized at a dif-
ferent institution. Finally, the generalizability of our study
may be limited by the clinical setting in which the obser-
vations were made. Some potential variability in patient
populations served by other VA facilities may limit the
generalizability of our findings.
Conclusion
This study highlights the importance of identifying the
reason for hospitalization among IBD patients. Patients
admitted for IBD-related reasons are more resource
intensive in terms of length of stay and use of surgical
procedures. Additionally, there was a tendency to-
wards a higher readmission rate in patients admitted
for IBD-related problems opposed to the other pa-
tients, although the difference did not reach statistical
significance. This issue may require confirmation with
a larger sample size. Finally, whether interventions fo-
cusing on care-coordination and communication at
the time of transition of care (i.e., discharge from the
hospital) reduce the readmission rate in IBD patients
should be addressed in a future study.
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